These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17034932)

  • 21. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats.
    De Young LX; Domes T; Lim K; Carson J; Brock GB
    Eur Urol; 2008 Jul; 54(1):213-20. PubMed ID: 18342431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P; Hedelin H; Ljunggren C
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
    Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
    Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vardenafil Bayer Yakuhin.
    Sommer F; Engelmann U
    Curr Opin Investig Drugs; 2002 Apr; 3(4):607-13. PubMed ID: 12090732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD; Beasley A; Blount MA; Francis SH
    Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
    Aliaev IuG; Vinarov AZ; Akhvlediani ND
    Urologiia; 2007; (1):45-6, 49. PubMed ID: 17471999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of the relaxant effect of vardenafil in rat penile arteries.
    Sánchez A; Villalba N; Martínez AC; García-Sacristán A; Hernández M; Prieto D
    Eur J Pharmacol; 2008 May; 586(1-3):283-7. PubMed ID: 18420189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating endothelial progenitor cells in subjects with erectile dysfunction.
    Foresta C; Caretta N; Lana A; Cabrelle A; Palù G; Ferlin A
    Int J Impot Res; 2005; 17(3):288-90. PubMed ID: 15729373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular studies of vardenafil].
    Jiang H
    Zhonghua Nan Ke Xue; 2005 May; 11(5):396-9. PubMed ID: 15934468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
    Sussman DO
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brachial flow-mediated dilation correlates with vardenafil response in hypertensive men with vasculogenic erectile dysfunction.
    Javaroni V; Queiroz-Miguez M; Abreu-Casanova M; Oigman W; Neves MF
    Urology; 2011 Aug; 78(2):368-74. PubMed ID: 21722944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
    Thadani U; Smith W; Nash S; Bittar N; Glasser S; Narayan P; Stein RA; Larkin S; Mazzu A; Tota R; Pomerantz K; Sundaresan P
    J Am Coll Cardiol; 2002 Dec; 40(11):2006-12. PubMed ID: 12475462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy.
    Hirschberg K; Radovits T; Loganathan S; Entz L; Beller CJ; Gross ML; Sandner P; Karck M; Szabó G
    J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1508-14. PubMed ID: 19464472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
    Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
    Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.